首页> 外文OA文献 >Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis

【2h】

Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis

机译：Ombitasvir，Paritaprevir和Ritonavir在有和没有肝硬化的基因型1b慢性丙型肝炎病毒感染患者的开放标签研究中的功效和安全性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Lawitz Eric; Makara Mihály; Akarca Ulus Salih; Thuluvath Paul J.; Preotescu Liliana Lucia; Varunok Peter; Morillas Rosa Mª.; Hall Coleen; Mobashery Niloufar; Redman Rebecca; Pilot-Matias Tami; Vilchez Regis A.; Hézode Christophe;
展开▼
作者单位

展开▼
年度 2015
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis [J] . Lawitz Eric, Makara Mihaly, Akarca Ulus Salih, Gastroenterology . 2015,第4期

机译：Ombitasvir，Paritaprevir和Ritonavir在有和没有肝硬化的基因型1b慢性丙型肝炎病毒感染患者的开放标签研究中的功效和安全性
2. Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low‐dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis [J] . Poordad Fred, Sedghi Shahriar, Pockros Paul J., Journal of viral hepatitis. . 2019,第8期

机译：慢性丙基肝炎病毒基因型1A感染患者慢性丙型肝炎病毒基因型1A感染患者的疗效和安全性的疗效和安全性和Dasbuvir
3. GEODE-II: Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Low-Dose Ribavirin QD in Patients with Genotype 1a Chronic Hepatitis C Virus Infection without Cirrhosis [J] . Poordad Fred, Sedghi Shahriar, Pockros Paul J., Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第S1期

机译：Geode-II：在患有Genotype 1A慢性丙基肝炎病毒感染的患者没有肝硬化的患者中患有低剂量利巴韦林QD的疗效和Dasbuvir和Dasbuvir的疗效和安全性
4. DIFFERENTIAL HUMORAL RESPONSE OF GENOTYPE IB HEPATITIS C VIRUS F PROTEIN BETWEEN CHRONIC AND RECOVERED INFECTIONS [C] . Deng Xiaozhao, Kong Jing, Chu Chunli, Progress on post-genome technologies and modern natural products . 2011

机译：慢性感染和康复感染之间基因型IB型肝炎C病毒F蛋白的差异性尿液反应
5. Population pharmacokinetics and efficacy of ribavirin in patients with chronic hepatitis C genotype 1 infection. [D] . Jin, Runyan. 2010

机译：利巴韦林在慢性丙型肝炎基因型1感染患者中的群体药代动力学和功效。
6. Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials [O] . Jason Grebely, Massimo Puoti, Heiner Wedemeyer, 2018

机译：Ombitasvir / Paritaprevir / Ritonavir和Dasabuvir联合或不联合利巴韦林在接受阿片类药物替代治疗的慢性丙型肝炎病毒基因型1感染患者中的疗效和安全性：对12项临床试验的事后分析
7. Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low‐dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis [O] . Fred Poordad, Shahriar Sedghi, Paul J. Pockros, 2019

机译：慢性丙基肝炎病毒基因型1A感染患者慢性丙基肝炎病毒基因型1A感染的疗效和Dasabuvir和Dasbuvir的疗效和安全性

Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis

著录项

相似文献

相关主题

期刊订阅